US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract, Snapshot, Market Analysis & Market Definition: World Immune Thrombocytopenia Drugs Market Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood. End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years. In 2020, the global Immune Thrombocytopenia Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2029, with a CAGR of xx% during 2021-2029. This report focuses on the global Immune Thrombocytopenia Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immune Thrombocytopenia Drugs development in United States, Europe and China Market Segmentation, Outlook & Viewpoint: World Immune Thrombocytopenia Drugs Market Segmentation by Product Type: Breakdown of data from the year 2015 to 2020 and forecast until 2029:
Segmentation by Application: Breakdown of data from the year 2015 to 2020 and forecast until 2029:
- Thrombopoietin Receptor Agonists (TPO-RAs)
- Intravenous Immunoglobins (IVIGs)
- Other Drug
Top Companies & Key Players: World Immune Thrombocytopenia Drugs Market
- Biotechnology and Pharmaceutical Companies
- Hospitals and Diagnostic Centers
- Academic Institutes and Research Organization
In Jan 2020, Instituto Grifols S.A. received marketing authorisation valid throughout the European Union for Tavlesse which is a medicine for treating adults with chronic immune thrombocytopenia. It is for use when other treatments have not worked. Chronic immune thrombocytopenia, previously called idiopathic thrombocytopenic purpura (ITP), is a long-term condition in which the immune system (the body’s defences) destroys healthy platelets in the blood. Platelets are needed to form clots and stop bleeding. Patients with the disease have low platelet counts and may bruise or bleed easily. Tavlesse contains the active substance fostamatinib. Tavlesse was found modestly effective for patients with immune thrombocytopenia when other treatments had not worked well enough and for whom there is no alternative treatment. Tavlesse can have serious side effects but they can be managed by taking precautions and reducing the dose. The European Medicines Agency therefore decided that Tavlesse’s benefits are greater than its risks and it can be authorised for use in the EU. Key Insights Covered: World Immune Thrombocytopenia Drugs Market 1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Immune Thrombocytopenia Drugs industry. 2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Immune Thrombocytopenia Drugs industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Immune Thrombocytopenia Drugs industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Immune Thrombocytopenia Drugs industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Immune Thrombocytopenia Drugs industry. Research Methodology: Global Immune Thrombocytopenia Drugs Market
- Amgen Inc.
- CSL Ltd.
- Horizon Therapeutics Plc
- Merck & Co., Inc.
- Novartis AG
- Rigel Pharmaceuticals Inc.
- Instituto Grifols S.A.
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.
1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered 1.4 Market Analysis by Type 1.4.1 Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type (2014-2025) 1.4.2 Thrombopoietin Receptor Agonists (TPO-RAs) 1.4.3 Corticosteroids 1.4.4 Intravenous Immunoglobins (IVIGs) 1.4.5 Other Drugs 1.5 Market by Application 1.5.1 Global Immune Thrombocytopenia Drugs Market Share by Application (2014-2025) 1.5.2 Biotechnology and Pharmaceutical Companies 1.5.3 Hospit | read more...